Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened

This article was originally published in The Pink Sheet Daily

Executive Summary

No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.

You may also be interested in...



Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing

Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert

Daiichi Sankyo Ranbaxy Acquisition Very Much Alive

Details of tender offer at 40 percent premium revealed.

Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK

Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel